Cancer
Malignant Prostate Neoplasm
CI-CAN-00005927Explore in graph →
Top-level1,377 active trials24 approved drugs58 evidence items
- NCIt
- C7378
- ICD-10
- C61
- DOID
- 10283
- Other
- 2 more codes
Loading cancer entity…
Loading cancer entity…
Cancer
CI-CAN-00005927Explore in graph →
Clinical trials
5,981 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (730)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02047253 | Phase 2 Trial of Carfilzomib for Metastatic Castration-resistant Prostate Cancer Following Treatment | completed | Phase 2 | 28 | University of Alabama at BirminghamOTHER | 1 | Dec 19, 2018 | clinicaltrials |
| NCT01832259 | A Study of VEGF Tyrosine Kinase Inhibitor (Pazopanib) in Men With High-Risk Prostate Cancer Followed by Radical Prostatectomy and Pelvic Lymph Node Dissection | completed | Phase 2 | 30 | University of UtahOTHER | 1 | Dec 12, 2018 |
| NCT00450463 | Vaccine Therapy With PROSTVAC/TRICOM and Flutamide Versus Flutamide Alone to Treat Prostate Cancer | completed | Phase 2 | 64 | National Cancer Institute (NCI)NIH | 1 | Nov 29, 2018 | clinicaltrials |
| NCT00499408 | Vitamin D and Soy Supplements in Treating Patients With Recurrent Prostate Cancer | completed | Phase 2 | 26 | Wake Forest University Health SciencesOTHER | 1 | Nov 21, 2018 | clinicaltrials |
| NCT00038181 | Preoperative Thalidomide Followed By Radical Retropubic Prostatectomy In Select Patients With Locally Advanced Prostate Cancer | completed | Phase 2 | 18 | M.D. Anderson Cancer CenterOTHER | 1 | Nov 15, 2018 | clinicaltrials |
| NCT02107430 | Phase II Study of DCVAC/PCa After Primary Radiotherapy for Patients With High Risk Localized Prostate Cancer | completed | Phase 2 | 62 | SOTIO a.s.INDUSTRY | 1 | Nov 14, 2018 | clinicaltrials |
| NCT00038246 | Study of Paclitaxel, Estramustine Phosphate and Thalidomide for Patients With Metastatic Androgen-Independent Prostate Carcinoma | completed | Phase 1 / Phase 2 | 40 | M.D. Anderson Cancer CenterOTHER | 1 | Oct 31, 2018 | clinicaltrials |
| NCT00384839 | Vidaza to Restore Hormone Thx Prostate | completed | Phase 2 | 36 | US Oncology ResearchINDUSTRY | 1 | Oct 25, 2018 | clinicaltrials |
| NCT00599313 | Phase II Sunitinib Prog Met AIPC | completed | Phase 2 | 36 | US Oncology ResearchINDUSTRY | 1 | Oct 25, 2018 | clinicaltrials |
| NCT01981122 | A Study of Sipuleucel-T With Administration of Enzalutamide in Men With Metastatic Castrate-Resistant Prostate Cancer | completed | Phase 2 | 52 | DendreonINDUSTRY | 1 | Oct 24, 2018 | clinicaltrials |
| NCT01091103 | Determine Effect of Enzalutamide (MDV3100) on the Androgen Signaling Pathway in Correlation With the Anti-tumor Effects of Enzalutamide | completed | Phase 2 | 60 | PfizerINDUSTRY | 1 | Oct 23, 2018 | clinicaltrials |
| NCT01547299 | Study of Enzalutamide (Formerly MDV3100) as a Neoadjuvant Therapy for Patients Undergoing Prostatectomy for Localized Prostate Cancer | completed | Phase 2 | 52 | PfizerINDUSTRY | 2 | Oct 23, 2018 | clinicaltrials |
| NCT01620710 | Safety Study of a Shorter (Hypofractionated) Radiotherapy for the Prostate Bed With or Without the Pelvic Lymph Nodes(PRIAMOS) | completed | Phase 2 | 80 | Heidelberg UniversityOTHER | 1 | Oct 16, 2018 | clinicaltrials |
| NCT02153918 | Vaccine Plus Booster Shots in Men With Prostate Cancer Undergoing Treatment With Radical Prostatectomy | completed | Phase 2 | 27 | National Cancer Institute (NCI)NIH | 1 | Oct 12, 2018 | clinicaltrials |
| NCT00942578 | A Phase 2 Trial of Bevacizumab, Lenalidomide, Docetaxel, and Prednisone (ART-P) for Treatment of Metastatic Castrate-Resistant Prostate Cancer | completed | Phase 2 | 63 | National Cancer Institute (NCI)NIH | 1 | Oct 11, 2018 | clinicaltrials |
| NCT00436956 | AZD2171 to Treat Prostate Cancer | completed | Phase 2 | 59 | National Cancer Institute (NCI)NIH | 1 | Oct 9, 2018 | clinicaltrials |
| NCT00634647 | Satraplatin and Prednisone to Treat Prostate Cancer | completed | Phase 2 | 24 | National Cancer Institute (NCI)NIH | 1 | Oct 2, 2018 | clinicaltrials |
| NCT01302041 | A Study to Test if Enzalutamide is Effective and Safe in Prostate Cancer Patients Who Have Never Had Hormone Therapy | completed | Phase 2 | 67 | Astellas Pharma IncINDUSTRY | 4 | Oct 2, 2018 | clinicaltrials |
| NCT01270880 | Hsp90 Inhibitor STA-9090 in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Chemotherapy | completed | Phase 2 | 18 | Barbara Ann Karmanos Cancer InstituteOTHER | 1 | Sep 18, 2018 | clinicaltrials |
| NCT01519414 | Tivantinib in Treating Patients With Metastatic Prostate Cancer | completed | Phase 2 | 78 | National Cancer Institute (NCI)NIH | 1 | Sep 12, 2018 | clinicaltrials |
| NCT00400517 | GM-CSF and Thalidomide in Treating Patients Undergoing Surgery for High-Risk Prostate Cancer | completed | Phase 2 | 28 | The Cleveland ClinicOTHER | 1 | Aug 28, 2018 | clinicaltrials |
| NCT01496157 | Evaluation of Prostate-specific Membrane Antigen (PSMA)-Based PET Imaging of Primary Prostate Cancer | completed | Phase 1 / Phase 2 | 15 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Aug 28, 2018 | clinicaltrials |
| NCT01815515 | Evaluation of 18F-DCFBC PSMA-based PET Imaging for Detection of Metastatic Prostate Cancer | completed | Phase 1 / Phase 2 | 22 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Aug 20, 2018 | clinicaltrials |
| NCT00004149 | Arsenic Trioxide in Treating Patients With Stage IV Prostate Cancer That Has Not Responded to Previous Hormone Therapy | completed | Phase 2 | 37 | Albert Einstein College of MedicineOTHER | 1 | Aug 17, 2018 | clinicaltrials |
| NCT00345813 | Soy Supplements in Treating Patients Undergoing Surgery for Localized Prostate Cancer | completed | Phase 2 | 62 | Wake Forest University Health SciencesOTHER | 1 | Aug 10, 2018 | clinicaltrials |
| NCT01260688 | Cediranib Maleate With or Without Dasatinib in Patients With HRPC-Resistant to Treatment With Docetaxel | completed | Phase 2 | 22 | National Cancer Institute (NCI)NIH | 2 | Aug 8, 2018 | clinicaltrials |
| NCT00223665 | Effects of IAS in Men With Localized Biochemical Relapsed Prostate Cancer(IAS) | completed | Phase 2 | 102 | University of WashingtonOTHER | 1 | Aug 7, 2018 | clinicaltrials |
| NCT00283803 | Exisulind and Intermittent Androgen Suppression (ADT) in Biochemical Relapsed Prostate Cancer | completed | Phase 2 | 32 | University of WashingtonOTHER | 1 | Aug 7, 2018 | clinicaltrials |
| NCT00039624 | Magnetic Resonance-Guided High-Dose Brachytherapy (Short-Range Radiation Therapy) for Prostate Cancer | completed | Phase 2 | 12 | National Cancer Institute (NCI)NIH | 1 | Aug 2, 2018 | clinicaltrials |
| NCT01656304 | Bevacizumab in Treating Patients With Relapsed Prostate Cancer That Did Not Respond to Hormone Therapy | completed | Phase 2 | 16 | Barbara Ann Karmanos Cancer InstituteOTHER | 1 | Jul 31, 2018 | clinicaltrials |
| NCT00520481 | Study With IMC-A12 (Cixutumumab) in Patients Who Have Not Previously Been Treated With Chemotherapy With Metastatic Prostate Cancer | completed | Phase 2 | 41 | Eli Lilly and CompanyINDUSTRY | 1 | Jul 19, 2018 | clinicaltrials |
| NCT01045109 | Vitamin D3 Supplementation in Participants Diagnosed With Early-Stage Prostate Cancer Who Decide to Undergo Active Surveillance Treatment Regimen.(D3/PCa) | completed | Phase 2 | 52 | Medical University of South CarolinaOTHER | 1 | Jul 18, 2018 | clinicaltrials |
| NCT01054079 | Cinacalcet Hydrochloride in Treating Men With Recurrent Prostate Cancer | completed | Phase 2 | 20 | Wake Forest University Health SciencesOTHER | 1 | Jul 5, 2018 | clinicaltrials |
| NCT00272038 | Single Agent Erlotinib in Chemotherapy-naive Androgen Independent Prostate Cancer | completed | Phase 2 | 29 | Oncology Specialists, S.C.OTHER | 1 | Jun 27, 2018 | clinicaltrials |
| NCT00165399 | Docetaxel, Estramustine and Short Term Androgen Withdrawal for Patients With a Rising PSA After Local Treatment | completed | Phase 2 | 62 | Dana-Farber Cancer InstituteOTHER | 1 | Jun 25, 2018 | clinicaltrials |
| NCT00090545 | A Phase II Study of BAY 43-9006 (Sorafenib) in Metastatic, Androgen-Independent Prostate Cancer | completed | Phase 2 | 46 | National Cancer Institute (NCI)NIH | 1 | Jun 14, 2018 | clinicaltrials |
| NCT01220973 | Atorvastatin Calcium and Celecoxib in Treating Patients With Rising PSA Levels After Local Therapy for Prostate Cancer | completed | Phase 2 | 27 | Rutgers, The State University of New JerseyOTHER | 1 | Jun 8, 2018 | clinicaltrials |
| NCT01521949 | Study of Acai Juice in Asymptomatic or Minimally Symptomatic Prostate Cancer Patients With Rising PSA | completed | Phase 2 | 21 | University of Colorado, DenverOTHER | 1 | Jun 6, 2018 | clinicaltrials |
| NCT01620593 | Castration Compared to Castration Plus Metformin as First Line Treatment for Patients With Advanced Prostate Cancer | completed | Phase 2 | 41 | The University of Texas Health Science Center at San AntonioOTHER | 1 | May 23, 2018 | clinicaltrials |
| NCT01090765 | A Phase I/II Study of TRC105 in Metastatic Castrate Resistant Prostate Cancer (CRPC) | completed | Phase 1 / Phase 2 | 21 | National Cancer Institute (NCI)NIH | 1 | May 22, 2018 | clinicaltrials |
| NCT00006101 | Eflornithine in Treating Patients At High Risk of Developing Prostate Cancer | completed | Phase 2 | 76 | Thomas E. AhleringOTHER | 1 | May 14, 2018 | clinicaltrials |
| NCT02083185 | A Phase 2 Study to Evaluate the Safety and Efficacy of TAK-385, Together With a Leuprorelin Observational Cohort, in Participants With Prostate Cancer | completed | Phase 2 | 136 | Millennium Pharmaceuticals, Inc.INDUSTRY | 2 | May 9, 2018 | clinicaltrials |
| NCT02130700 | Oral VT-464 in Patients With Castration-Resistant Prostate Cancer Previously Treated With Enzalutamide, Androgen Receptor Positive Triple-Negative Breast Cancer Patients, and Men With ER Positive Breast Cancer | completed | Phase 2 | 17 | Innocrin PharmaceuticalINDUSTRY | 1 | May 7, 2018 | clinicaltrials |
| NCT00513071 | AZD0530 in Treating Patients With Prostate Cancer That Did Not Respond to Hormone Therapy | completed | Phase 2 | 28 | National Cancer Institute (NCI)NIH | 1 | Apr 19, 2018 | clinicaltrials |
| NCT01666314 | Study in Japan and Ex-Japan to Characterize the Pharmacokinetic and Pharmacodynamic Response to Orteronel (TAK-700) in Chemotherapy-Naive Participants With Castration-Resistant Prostate Cancer | completed | Phase 1 / Phase 2 | 137 | Millennium Pharmaceuticals, Inc.INDUSTRY | 1 | Mar 20, 2018 | clinicaltrials |
| NCT02488070 | 68Ga-PSMA PET/CT or PET/MRI in Evaluating Patients With Recurrent Prostate Cancer | completed | Phase 1 / Phase 2 | 10 | Stanford UniversityOTHER | 1 | Mar 20, 2018 | clinicaltrials |
| NCT00888654 | Diindolylmethane in Treating Patients With Stage I or Stage II Prostate Cancer Undergoing Radical Prostatectomy | completed | Phase 2 | 41 | Barbara Ann Karmanos Cancer InstituteOTHER | 1 | Mar 19, 2018 | clinicaltrials |
| NCT01393730 | Abiraterone Acetate Combined With Dutasteride for Metastatic Castrate Resistant Prostate Cancer | completed | Phase 2 | 40 | Mary-Ellen Taplin, MDOTHER | 1 | Mar 15, 2018 | clinicaltrials |
| NCT01496131 | Tecemotide (L-BLP25) in Prostate Cancer | completed | Phase 2 | 28 | EMD SeronoINDUSTRY | 1 | Mar 9, 2018 | clinicaltrials |
| NCT02796807 | Correlation Between SUV on 68Ga-HBED-CC-PSMA and Gleason Score in Prostate Cancer | completed | Phase 2 | 88 | Sir Mortimer B. Davis - Jewish General HospitalOTHER | 1 | Mar 6, 2018 | clinicaltrials |
Data updated 23 days agoSource updated Dec 19, 2018source: clinicaltrials